These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36352054)

  • 1. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.
    Fontes MSC; Dingemanse J; Halabi A; Tomaszewska-Kiecana M; Sidharta PN
    Sci Rep; 2022 Nov; 12(1):19067. PubMed ID: 36352054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
    Sidharta PN; Ulč I; Dingemanse J
    Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
    Sidharta PN; Melchior M; Kankam MK; Dingemanse J
    Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
    Fontes MSC; Dingemanse J; Sidharta PN
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
    Sidharta PN; Dingemanse J
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects.
    Sidharta PN; Dingemanse J
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):227-234. PubMed ID: 31773427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
    Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
    Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.
    Bruderer S; Detishin V; Tsvitbaum N; Dingemanse J
    Br J Clin Pharmacol; 2011 Jan; 71(1):52-60. PubMed ID: 21143501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension.
    Brussee JM; Sidharta PN; Dingemanse J; Krause A
    J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):243-252. PubMed ID: 38332190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
    Sidharta PN; Fischer H; Dingemanse J
    Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
    Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
    Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.
    Mercier AK; Sunnåker M; Ueckert S; Pawlik T; Henricson E; Molodetskyi O; Law GC; Parker VER; Oscarsson J
    Clin Pharmacokinet; 2023 Dec; 62(12):1713-1724. PubMed ID: 37801266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.
    Bartolucci R; Dosne AG; Csonka D; Pérez-Ruixo JJ; Magni P; Poggesi I
    Clin Pharmacokinet; 2021 Dec; 60(12):1605-1619. PubMed ID: 34159557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.
    Sidharta PN; Lindegger N; Ulč I; Dingemanse J
    J Clin Pharmacol; 2014 Mar; 54(3):291-300. PubMed ID: 24122797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
    Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
    Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
    Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
    BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib.
    Gao L; Yamamiya I; Pinti M; Rondon JC; Marbury T; Tomlinson G; Makris L; Hangai N; Wacheck V
    Clin Transl Sci; 2023 Sep; 16(9):1713-1724. PubMed ID: 37553804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.